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Abstract
Background: Helicobacter pylori (H. pylori) is associated with an increased risk of gastric adenocarcinoma and gastric mucosa
associated lymphoid tissue (MALT) lymphoma and a decreased risk of esophageal adenocarcinoma. We aimed to assess how
eradication therapy for H. pylori influences the risk of developing these cancers.
Methods: This was a systematic review and meta-analysis. We searched PubMed, Web of Science, Embase, and the Cochrane
Library and selected articles that examined the risk of gastric cancer, MALT lymphoma, or esophageal cancer following eradi-
cation therapy, compared with a noneradicated control group.
Results: Among 3629 articles that were considered, nine met the inclusion criteria. Of these, eight cohort studies assessed
gastric cancer while one randomized trial assessed esophageal cancer. Out of 12 899 successfully eradicated patients, 119 (0.9%)
developed gastric cancer, compared with 208 (1.1%) out of 18 654 noneradicated patients. The pooled relative risk of gastric
cancer in all eight studies was 0.46 (95% confidence interval [CI] ¼ 0.32 to 0.66, I2 ¼ 32.3%) favoring eradication therapy. The four
studies adjusting for time of follow-up and confounders showed a relative risk of 0.46 (95% CI¼0.29 to 0.72, I2 ¼ 44.4%).
Conclusions: This systematic review and meta-analysis indicates that eradication therapy for H. pylori prevents gastric can-
cer. There was insufficient literature for meta-analysis of MALT lymphoma or esophageal cancer.
Helicobacter pylori is a bacterium estimated to be present in the
stomachs of half of the adult human population and is typically
acquired during childhood (1,2). H. pylori is associated with
chronic gastritis, peptic ulcer, and gastric cancer, particularly in
the presence of its virulence factor CagA (3). The incidence of
gastric cancer is declining, possibly because of the decrease in
H. pylori prevalence (4), but is still the fifth most common cancer
and the third most common cause of cancer death globally (5).
The overall yearly incidence rates globally are 15.6 to 18.1 and
6.7 to 7.8 per 100 000 individuals in men and women, respec-
tively (6). There are considerable variations in incidence geo-
graphically, and half of all cases occur in Eastern Asia (5).
Gastric cancer is typically adenocarcinoma (95%), which is
subclassified into intestinal or diffuse type, both associated
with H. pylori (7–9), and mixed type. The intestinal type develops
from a gastric mucosa with chronic gastritis, atrophy, intestinal
metaplasia, and dysplasia to invasive adenocarcinoma (10). For
the diffuse type, the carcinogenic pathway is less clear. The re-
maining adenocarcinomas are of the mixed type. Gastric
mucosa–associated lymphoid tissue (MALT) lymphomas are
also associated with H. pylori (11). Interestingly, H. pylori seem-
ingly decreases the risk of esophageal adenocarcinoma (12). A
possible explanation is that H. pylori–related atrophic gastritis
reduces gastric acid secretion, which in turn counteracts gastro-
esophageal reflux, a main risk factor for this cancer (12). The in-
creasing incidence of esophageal adenocarcinoma might be
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because of the decreasing prevalence of H. pylori (13). CagA-
positive H. pylori strains might also be associated with an in-
creased risk of esophageal squamous cell carcinoma (14). In the-
ory, H. pylori eradication should reduce the risk of gastric
adenocarcinoma, MALT lymphoma, and esophageal squamous
cell carcinoma and increase the risk of esophageal adenocarci-
noma. However, the available literature is limited. Two previous
meta-analyses have indicated a decreased risk of gastric adeno-
carcinoma while no meta-analysis has examined MALT lym-
phoma or esophageal cancer (15,16). We aimed to examine the
role of H. pylori eradication therapy in the development of gas-
tric adenocarcinoma, MALT lymphoma, and esophageal cancer
in a systematic review and meta-analysis.
Methods
This was a systematic review and meta-analysis analysing the
risk of gastric adenocarcinoma, MALT lymphoma, and esopha-
geal cancer after eradication therapy for H. pylori. The study was
performed according to an a priori established study protocol.
Exposure and Outcome
The study exposure was H. pylori eradication therapy. All regi-
mens intended to eradicate H. pylori were considered eligible.
H. pylori–positive individuals who did not receive eradication
and individuals for whom eradication was unsuccessful were
considered unexposed (noneradicated). The outcomes were gas-
tric or esophageal malignancy, where the following histological
subtypes were considered for inclusion: adenocarcinoma, squa-
mous cell carcinoma, or MALT lymphoma (17,18).
Search Strategy and Study Selection
We conducted a systematic search of the medical literature us-
ing PubMed, Web of Science, Embase, and the Cochrane Library
up until November 2015. There were no restrictions regarding
article language or date of publication. Articles were considered
eligible if the risk of cancer was evaluated in individuals receiv-
ing eradication therapy, compared with a control group that
did not receive eradication or in which eradication was unsuc-
cessful. Only studies describing a population representative
of the general population or representative of individuals receiv-
ing H. pylori screening and treatment in clinical practice
were considered eligible. The following search terms were
used: ‘Helicobacter pylori,’ ‘campylobacter,’ ‘eradication,’ ‘chemo-
prevention,’ ‘esophageal neoplasms,’ ‘esophageal,’ ‘stomach
neoplasms,’ ‘gastric,’ ‘cancer,’ ‘carcinoma,’ ‘tumour,’ ‘adenocar-
cinoma,’ ‘malignancy’ (taking into account both British and
American spelling), and the names of different medications
used for H. pylori eradication. A detailed search description can
be found in the Supplementary Materials (Supplementary Table
1, available online). The results of the search were first evalu-
ated based on article titles by one researcher (ED). The next step
of the search was performed by two independent researchers
(ED and NB), who evaluated the abstracts and full texts of the re-
maining articles. Any disagreement between the researchers
was solved by consensus. Initial exclusion criteria were animal
studies, studies without original data (including commentaries
and editorials), meeting abstracts, case reports, and case-
control studies. The latter were excluded to maintain compara-
bility of measures of effect. Furthermore, we applied backwards
and forward citation tracking (sources cited in included articles
and identifying articles that cited the included articles) to all in-
cluded articles to identify other possible relevant studies. For
studies that reported cancer development after eradication
therapy for H. pylori but did not report the number of cancer
cases in the control group, we contacted the authors to provide
these data to be able to include these articles. When we found
multiple articles based on the same study population, we in-
cluded only the most recent article (with the longest follow-up).
Data Extraction and Quality Assessment
Data extraction on cancer development was performed inde-
pendently by two researchers (ED and NB), who extracted both
unadjusted data (ie, absolute numbers) and adjusted data while
taking into account the follow-up time (from Cox or Poisson
models). The following data were extracted for each study: geo-
graphical location, method to detect H. pylori, H. pylori eradica-
tion regimen, success of eradication, age (mean and range), sex
ratio, follow-up time, and the histological type of the cancer.
Two researchers (ED and NB) independently assessed the
quality of the studies according to the Newcastle Ottawa scale
(19). The quality of each study was assessed by the following
items: representativeness of the exposed cohort, selection of
the nonexposed cohort, ascertainment of the exposure, demon-
stration that the outcome of interest was not present at the on-
set of the study, comparability of study cohorts on the basis of
the design or analysis, assessment of outcome, length and ade-
quacy of the follow-up of the cohorts. Studies with a score of 3
or less were considered of low quality, 4 and 5 were considered
of moderate quality, and a score of 6 or higher defined good
quality.
Data Synthesis and Statistical Analysis
For the pooled analyses, we used a random effect model to take
heterogeneity within and between studies into account, there-
fore estimating the average treatment effect and its precision.
H. pylori eradication was compared with no eradication or un-
successful eradication and expressed as unadjusted risk ratios
(RRs) with 95% confidence intervals (CIs) for the development of
cancer. A second analysis was used to pool the adjusted risk ra-
tios and 95% confidence intervals, taking into account follow-up
time, in which the adjusted (full model) reported hazard or inci-
dence ratios that were used. To assess heterogeneity, we used
the I2 statistic, where an I2 of greater than 50% was used to de-
fine a substantial degree of heterogeneity (20). The statistical
significance of heterogeneity was assessed with a Cochran’s Q
test, with values smaller than 0.10 representing substantial het-
erogeneity. Subgroup analyses were performed for baseline gas-
tric histology, and type of control group to investigate possible
explanations for any heterogeneity. A funnel plot and Egger’s
test were conducted, where a large P value (>.05) indicated no
evidence of small study effects or publication bias. All statistical
tests were two-sided. The statistical analyses were performed
using the statistical software Stata (Stata Corporation, version
12.1).
Results
Study Selection
The systematic search identified 3629 unique articles (Figure 1).
After screening of the titles and abstracts, the full texts of 38
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articles remained for further evaluation of eligibility. None of
these studies assessed the risk of MALT lymphoma, and only
one study assessed the risk of esophageal cancer (21). Four stud-
ies were excluded because of the design; one was a case-control
study (22), and three others were comments without original
data (23–25). Three studies were excluded because they were re-
views or gave notice of an ongoing study and thus contained no
new data (26–28). Other studies were excluded for various rea-
sons as shown in Figure 1 (29–32). Nine studies were random-
ized controlled trials (RCTs) already described in the most
recent meta-analysis (21,33–40), and no new RCTs were identi-
fied after that meta-analysis (15). After this evaluation of the lit-
erature, we restricted our study to cohort studies when
examining gastric cancer. Seven other articles were excluded
because no suitable control group was described (41–45) or the
risk of cancer was not reported in the control group; we did not
retrieve this information after contacting the authors (46,47). Four
other articles described the cancer risk based on the same popu-
lation (48–51), so only the most recent article with the longest
follow-up was included (51). After this review, eight observational
studies assessing the risk of gastric cancer were selected for final
analysis (51–58). One study, a randomized clinical trial assessing
the risk of esophageal cancer, was included (21).
Study Characteristics
Patient characteristics for the eight studies examining gastric
cancer are presented in Table 1. Seven of the studies were con-
ducted in Japan and one in Finland. Five studies compared a
successful with an unsuccessful eradication attempt (51–55),
and three studies compared eradicated individuals with
Articles identified through database 
searches (PubMed, Web of Science, 
Embase) 
(n=4729) 
Additional articles identified 
through other sources 
(n=1) 
Articles after duplicates removed 
(n=3629) 
Articles screened 
(n=3629) 
Articles excluded 
(n=3591) 
Full-text articles assessed 
for eligibility 
(n=38) 
Full-text articles excluded, 
with reasons 
Randomized 
clinical trials 
(n=9) 
Case-control study 
(n=1) 
Comment (n=3) 
Exposure of 
antibiotic use 
(n=1) 
Unclear study 
(n=1) 
No new 
data/review (n=3) 
No outcomes yet 
(n=1) 
Conference 
abstract (n=1) 
No suitable 
control group 
(n=7) 
Data on same 
population (n=3) 
Articles included in 
qualitative synthesis 
(n=8) 
Articles included in 
quantitative synthesis 
(meta-analysis) 
(n=8) 
Figure 1. Flow diagram of study selection adapted from Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for a meta-analysis assessing
gastric cancer risk after Helicobacter pylori eradication.
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untreated individuals with H. pylori (56–58). The age range was
17 to 83 years (51), with mean ages between 50 (51) and 63 years
(57). Most studies included more men than women (Table 1),
particularly in one of the studies on factory workers (98% men)
(56). Three studies described the baseline gastric histopathology
of the patients while the other five did not. In one study, all pa-
tients (100%) had gastric atrophy (51), and in another study only
5% to 7% had atrophic gastritis (53). One study included patients
with intestinal metaplasia and a large (undefined) proportion of
participants who presented with atrophy at baseline (58). None
of the studies included patients with dysplasia or early gastric
cancer at baseline. Table 2 describes the eradication therapies
used. Success of eradication was measured in five out of eight
studies, and the success rate varied between 65% (55) and 87%
(56). Gastric cancer development and follow-up of patients is
described in Table 3. The mean follow-up time ranged from 2.9
years (53) to 10.9 years (52). The majority (up to 89%) of the can-
cers in both treatment and control groups were intestinal-
type gastric adenocarcinomas. In the treatment group in one
study (51) and the control group of another study (55), there
were similar proportions of diffuse and intestinal-type
adenocarcinomas.
Quality Assessment of Included Studies
Of the eight studies, seven were considered of good quality (51–
56,58) and one of moderate quality (57). All studies included a
control group from the same community as the exposed group
and had a good ascertainment of the outcome. All but one study
had a good assessment of the exposure, yet in one study it was
not clear if eradication was successful in all patients because of
incomplete data (52). In two studies, the eradicated group was a
selected group of individuals (ie, factory workers) (51,56). One
study could not demonstrate that gastric cancer was not pre-
sent at start (52). Two studies had a rather short follow-up time,
with a mean around three years (53,57). One study had a limited
completeness of follow-up (56%) and no description of the indi-
viduals lost to follow-up (57), and one study had no statement
about follow-up of the cohort members (54). Four studies re-
ported risk estimates adjusted for time for follow-up and con-
founding (51,53,55,57). The confounders adjusted for were not
specified in one study (57) while the other three studies ad-
justed for age and sex. One study further adjusted for alcohol
use, tobacco smoking, and gastric mucosal atrophy (51), another
adjusted for the indication for H. pylori eradication (53), and the
last one also adjusted for location of peptic ulcer, salt consump-
tion, and tobacco smoking (55).
Helicobacter pylori Eradication Therapy and Gastric
Cancer Risk
Among 12 899 patients who were successfully eradicated, 119
(0.9%) developed gastric cancer during follow-up while such
cancer was found in 208 out of 18 654 (1.1%) in the noneradi-
cated group. The pooled analysis of all eight included studies
provided a risk ratio of 0.46 (95% CI¼ 0.32 to 0.66) in favor
of eradication therapy (Figure 2). The heterogeneity was low
(I2 ¼ 32.3%), and there was no evidence of small study effects or
publication bias (P ¼ .33). When the Finnish study was excluded,
because of the low incidence of gastric cancer in Finland com-
pared with East-Asian countries, the seven Japanese studies
provided a pooled risk ratio of 0.40 (95% CI¼ 0.29 to 0.54, I2 ¼
0.0%). Another sensitivity analysis excluding the study where a
proportion of the participants had intestinal metaplasia at base-
line yielded a risk ratio of 0.48 (95% CI¼ 0.34 to 0.66, I2 ¼ 24.2%).
The five studies comparing successful vs unsuccessful eradica-
tion showed a risk ratio of 0.47 (95% CI¼ 0.31 to 0.71, I2 ¼ 40.9%),
and the three studies comparing eradicated with noneradicated
individuals showed a risk ratio of 0.39 (95% CI¼ 0.14-1.08, I2 ¼
49.9%) (Figure 2). The five studies not reporting baseline gastric
histopathology (atrophy, intestinal metaplasia, or dysplasia)
showed a risk ratio of 0.52 (95% CI¼ 0.35 to 0.77, I2 ¼ 35.7%), and
the three studies including patients with aberrant baseline his-
tology (gastric atrophy or intestinal metaplasia) showed a risk
ratio of 0.28 (95% CI¼ 0.11 to 0.72, I2 ¼ 40.9%) (forest plot not
shown). Four studies reported risk ratios adjusted for follow-up
time and confounding, of which three were analyzed using Cox
regression and one using Poisson regression, resulting in a
pooled adjusted risk ratio of 0.46 (95% CI¼ 0.29 to 0.72, I2 ¼
44.4%), 0.33 (95% CI¼ 0.19 to 0.59) when including only the three
studies using Cox regression (I2 ¼ 0%), indicating a low hetero-
geneity between these three studies (Figure 3).
Helicobacter pylori Eradication Therapy and esophageal
Cancer Risk
The only study assessing the risk of esophageal cancer was per-
formed in China and compared eradication with placebo treat-
ment (21). The mean age was 42 years (range ¼ 35–65), and the
proportion of men to women was similar in both groups. The
Table 1. Patient characteristics of studies included in a meta-analysis of Helicobacter pylori eradication and risk of gastric cancer*
Study
Males receiving
eradication, %
Male control
subjects, %
Age range
among all included
individuals, y
Mean age for
those receiving
eradication, y
Mean age
among control
subjects, y
Baseline histology
of the gastric
mucosa
Uemura, 2001 57 NA 20-76 52 NA 53% moderate atrophy, 17%
severe atrophy
37% intestinal metaplasia
Kato, 2006 66 57 NA 55 53 Not reported
Takenaka, 2007 71 NA NA 54 NA 5-7% atrophic gastritis
Ogura, 2008 57 55 NA 62 63 Not reported
Mabe, 2009 71 71 NA 52 58 Not reported
Yanaoka, 2009 98 NA 40-60 NA NA Not reported
Kosunen, 2011 44 44 NA 56 55 Not reported
Take, 2014 89 NA 17-83 50 NA 100% atrophy (mild to severe)
*NA ¼ not available.
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eradication rate was 84%. Two out of 817 (0.2%) individuals who
received eradication therapy developed esophageal cancer,
compared with one out of 813 (0.1%) individuals who received
placebo; all three cancers were squamous cell carcinomas (21).
Discussion
This meta-analysis indicates that eradication therapy for H. py-
lori prevents gastric adenocarcinoma. The literature is insuffi-
cient to allow analysis of the risk of MALT lymphoma or
esophageal cancer following eradication in a meta-analysis.
The main strength of this meta-analysis is that by including
only cohort studies we were able to conduct an objective analy-
sis on a large number of participants over a long follow-up pe-
riod. The eight included studies are based on cohorts close to
clinical practice without obvious selection issues. The fact that
the studies presenting both unadjusted and adjusted results
showed similar effect sizes indicates lack of strong confounding
by the factors adjusted for. Also, this study was based on an a
priori established study protocol and a thorough systematic
search of the literature.
Limitations of meta-analyses in general are that the validity
is dependent on the quality of the included studies, on hetero-
geneity between studies, and on possible publication bias. Also,
by using cohort studies there is a higher risk of uncontrolled
bias, mainly confounding. However, it is important to assess
the effect from studies that closer resemble clinical practice,
and the quality was considered good in seven out of eight stud-
ies and moderate in one; the statistical heterogeneity was low
to moderate, and there was no evidence of small-study effects
bias (publication bias). Moreover, the results were consistent in
various sensitivity analyses. Analysis of studies comparing
eradicated individuals with individuals not having undergone
any attempt to treat the bacteria and studies comparing eradi-
cated individuals with unsuccessfully eradicated individuals
showed similar results. However, four out of eight studies did
not adjust for confounders, and the four studies that did ad-
justed for different confounders. Because of this, confounding
might still influence the results, limiting comparability.
However, we assessed the quality of the included studies, and
almost all were of good quality. Furthermore, a quality assess-
ment tool is very useful to compare included studies in an ob-
jective way. However, this tool cannot take other items into
account, for example, the extent of missing data in the individ-
ual studies. Missing data items in this study mostly concern the
reporting of age. This was most serious in one study, where
only the age range for all participants was reported and no
mean ages for both treatment and control group were reported
(56). The detection of H. pylori and consequent evaluation of
success of eradication may have influenced the results, espe-
cially in the Finnish study, where success of eradication was
less clearly defined (a large proportion of patients did not have
information regarding cure) (52). Outcome was measured with
endoscopy in seven studies and extracted from a cancer registry
in one study (52). Of the seven studies assessing the outcome
endoscopically, three reported doing this on an annual basis
(51,53,55). There was no additional information in the other
four studies. This makes it difficult to compare these studies. In
three studies, patients presented with atrophy or intestinal
metaplasia at baseline (51,53,58). There were two studies per-
formed on a selected group, namely male factory workers, who
are likely to be healthier than the general population (“healthy
worker effect”) (59). A limitation was that almost all studiesT
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Figure 2. Forest plot of studies comparing eradication therapy to no treatment and studies comparing successful to unsuccessful treatment. A random effects model
(DerSimonian Laird method) was used. The I2 was used to assess heterogeneity. The two-sided Cochran’s Q test was used to assess the significance of this heterogene-
ity. The diamond represents the observed effect size for the studies combined, the squares represent the weight given to the study, and the error bars represent the
corresponding confidence intervals. CI ¼ confidence interval; RR ¼ relative risk.
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Figure 3. Forest plot of studies comparing eradicated and noteradicated groups that reported adjusted values, grouped by Cox or Poisson model. A random effects
model (DerSimonian Laird method) was used. The I2 was used to assess heterogeneity. The two-sided Cochran’s Q test was used to assess the significance of this het-
erogeneity. The diamond represents the observed effect size for the studies combined, the squares represent the weight given to the study, and the error bars represent
the corresponding confidence intervals. CI ¼ confidence interval; NA ¼ not available; RR ¼ relative risk.
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were conducted in Japan, an area with a high incidence of gas-
tric cancer, which questions whether the results are generaliz-
able to non-Asian populations.
The finding that H. pylori eradication therapy prevents gastric
cancer is in line with the findings of two previous meta-analyses
based on randomized clinical trials (15,16). The relative risk of
gastric cancer after eradication therapy compared with placebo
or no treatment was 0.66 (95% CI¼ 0.46 to 0.95) in the most recent
meta-analysis, and thus our meta-analysis yielded a stronger
preventive effect. The earlier meta-analysis was performed on
the same randomized clinical trials but included data from one
randomized clinical trial twice (16,60). Compared with the most
recent meta-analysis, which investigated the risk of gastric can-
cer after H. pylori eradication in healthy asymptomatic individuals
in six individual randomized clinical trials with follow-up ranging
from maximum five to 14.7 years (15), the present meta-analysis
included studies with a longer follow-up (up to 20 years) (52) and
almost four times more treated individuals and more than five
times more controls. Most of the randomized clinical trials in-
cluded in the previous meta-analyses were conducted in China,
leading to a limited generalizability of the results (similar to the
present study). Also, the results for these studies are relevant
mainly for otherwise healthy individuals whereas the result of
our study would be more applicable to the general patient popu-
lation. Furthermore, cohort studies better resemble clinical prac-
tice and reduce selection of participants compared with
randomized clinical trials.
There is a debate whether H. pylori eradication prevents gas-
tric cancer. There are suggestions that once the histology has
reached the level of intestinal metaplasia in the gastric adeno-
carcinoma development pathway eradication therapy may no
longer have cancer-preventive effects (61). However, it is likely
that H. pylori eradication lowers the risk of gastric cancer com-
pared with no treatment (62), which is supported by the findings
of the present meta-analysis and the two previous meta-
analyses. H. pylori is more strongly associated with the risk of
intestinal type of gastric adenocarcinoma than with the diffuse
type (63). In one study, it was suggested that H. pylori eradication
would prevent only the intestinal type because the diffuse type
developed only in individuals cured from H. pylori infection (48).
In the present study, the results indicate a similarly strong pre-
ventive role of eradication for both histological types of gastric
adenocarcinoma. Because the included studies did not provide
information on the location of gastric cancer (cardia or noncar-
dia), no conclusion can be drawn of the effect of eradication for
different anatomical locations of gastric cancer.
To conclude, this systematic review and meta-analysis of
eight cohort studies and 31 553 patients indicates that eradica-
tion therapy for H. pylori prevents gastric cancer. Research ex-
amining H. pylori eradication in relation to the risk of gastric
MALT lymphoma and esophageal cancer is currently too limited
to enable meta-analyses. More studies assessing the risk of
esophageal cancer and MALT lymphoma after H. pylori eradica-
tion are needed. Because both types of cancers are rare com-
pared with gastric cancer, RCTs may not have enough power.
Thus, population-based studies may be preferred.
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